Madrigal Pharmaceuticals

$111.94
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$1.32 (-1.17%) Today

$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell MDGL and other stocks, options, and ETFs commission-free!

About MDGL

Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA. The listed name for MDGL is Madrigal Pharmaceuticals, Inc. Common Stock.

CEO

Paul A. Friedman

Employees

Headquarters

West Conshohocken, Pennsylvania

Founded

2011

Market Cap

1.73B

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

153.98K

High Today

$114.48

Low Today

$111.81

Open Price

$114.06

Volume

94.91K

52 Week High

$137.28

52 Week Low

$56.82

Collections

Medical

Pharmaceutical

Research And Development

Health

Cancer Prevention

Technology

Analyst Ratings

76%

of 17 ratings

Buy

76%

Hold

18%

Sell

MDGL Earnings

-$3.75

-$2.50

-$1.25

$0.00

Q1 FY19

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Expected Feb 24, Pre-Market